United States · Platforms & data · MarketBeat

Altimmune (NASDAQ:ALT) Stock Keeps Buy Rating at B. Riley Financial

Published by MarketBeat · United States 1 d ago

Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

B. Riley Financial reissued a "buy" rating and set a $11.00 price objective (down from $13.00) on shares of Altimmune in a report on Friday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

‘It leaves me with a sour taste’: My elderly mother gave our cousin $800 for a car repair. Should I be worried?

Insider trades: Microsoft, Netflix, Boeing among notable names

The Motley Fool

Firefly Aerospace vs. Redwire: Which Industrials Stock Is a Better Buy for 2027?

Thousands of US flights canceled, delayed as air travel system recovers from shutdown

Eric Trump-backed robot soldier startup can't pay staff after founder borrowed $4.6 million from company to buy home

Costco solves a problem Sam’s Club hasn’t figured out yet